DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-717/S-005

Forest Laboratories, Inc.
Attention: Amjad M. Iqbal, PharmD
Assistant Director, Regulatory Affairs
Harborside Financial Center
Plaza Three, Suite 602
Jersey City, New Jersey 07311

Dear Dr. Iqbal:

Please refer to your supplemental new drug application dated July 31, 2007, received August 1, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Monurol™ (fosfomycin tromethamine) Sachet.

This "Changes Being Effected" supplemental new drug application provides for revisions to the package insert to include information relative to recent epidemiologic and scientific data regarding *Clostridium difficile* associated disease (CDAD).

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on July 31, 2007.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kyong Hyon, Regulatory Project Manager, at (301) 796-0734.

Sincerely,

{See appended electronic signature page}

Katherine Laessig, M.D.
Deputy Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Labeling submitted on July 31, 2007

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kathrine Laessig
3/11/2008 11:19:19 AM